EUVIMEDEUVIMED entdecken
Open Access

NBR1-Mediated Autophagic Degradation of YTHDF1 Curtails FDX1 Translation to Drive Concurrent Multikinase Inhibitor Resistance and Cuproptosis Tolerance

Weikai Wang, Xin Jiang, Xiaona Chen, Kaiyu Liang, Miaoqin Chen, Kaizhong Lu, Qi Wei, Yuchen Wu, Liyuan Zhu, Yuan Chen, Tianlun Hou, Jingfeng Luo und 4 weitere

Cancer Communications · 2026

DOI: 10.34133/cancomm.0048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2026. Verfasst von Weikai Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Sir Run Run Shaw Hospital…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, RNA-Binding Proteins, Protein Kinase Inhibitors, Liver Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer cells frequently acquire adaptive resistance to targeted therapies; however, strategies capable of concurrently overcoming treatment tolerance and reactivating cell death pathways are currently lacking. Here, we investigated the dual role of ferredoxin 1 (FDX1) in modulating both multikinase inhibitor (MKI) sensitivity and cuproptosis susceptibility in hepatocellular carcinoma (HCC), and sought to develop a therapeutic approach for reversing resistance.

Methods

HCC models, both in vitro and in vivo, were employed to investigate the role of FDX1 in MKI resistance and cuproptosis evasion. Polysome profiling, SunTag translation reporters, CRISPR-Cas9 mutagenesis, and mass spectrometry were employed to delineate the underlying mechanisms. A codelivery nanoliposome system was engineered and tested in orthotopic HCC models.

Results

Prolonged exposure to MKIs led to the down-regulation of FDX1 protein levels, resulting in MKI resistance and cuproptosis tolerance in HCC both in vitro and in vivo. Mechanistically, we found that MKIs inactivated protein kinase B (PKB, also known as AKT)-mechanistic target of rapamycin (mTOR) signaling, thereby suppressing the SET and MYND domain-containing protein 2 (SMYD2)-mediated methylation of YTH domain family protein 1 (YTHDF1) at lysine 515 (K515). Hypomethylated YTHDF1 was degraded via next to BRCA1 gene 1 protein (NBR1)-dependent autophagy, leading to the repression of N6-methyladenosine modification-dependent translation of FDX1 mRNA. FDX1 deficiency drove MKI resistance by reactivating AKT survival signaling while impairing cuproptosis through reduced divalent copper ions (Cu 2+ ) to monovalent copper ions (Cu + ) conversion and the loss of protein lipoylation. Additionally, restoring FDX1 expression through NBR1 knockdown or YTHDF1 overexpression overcame MKI resistance and resensitized HCC cells to cuproptosis. Finally, a nanoliposomal system, super cuproptosis detonator liposome, designed for the codelivery of NBR1 small interfering RNA, a copper ionophore, and sorafenib restored FDX1-dependent cuproptosis and exhibited marked anti-HCC efficacy, suppressing HCC growth in vivo.

Conclusions

MKIs suppressed SMYD2-mediated YTHDF1 methylation at K515 via the inactivation of AKT-mTOR signaling. This led to the inhibition of FDX1 translation, resulting in AKT signaling reactivation and protein lipoylation impairment, effects that contributed to both MKI resistance and cuproptosis tolerance in HCC. Overcoming MKI resistance and resensitizing cells to cuproptosis by targeting NBR1-mediated YTHDF1 degradation using a nanoliposomal codelivery system represents a promising strategy for HCC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmRNA-Binding ProteinsProtein Kinase InhibitorsLiver NeoplasmsCarcinoma, HepatocellularCuproptosisHumansAnimalsMiceAutophagyCell Line, TumorXenograft Model Antitumor AssaysIntracellular Signaling Peptides and Proteins

Substanzen

RNA-Binding ProteinsProtein Kinase InhibitorsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Medical Oncology, Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. C…
  • Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, P. R. China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Wang, W., Jiang, X., Chen, X., Liang, K., Chen, M., Lu, K., Wei, Q., Wu, Y., Zhu, L., Chen, Y., Hou, T., Luo, J., Li, C., Wang, X., Jin, H., & Feng, L. (2026). NBR1-Mediated Autophagic Degradation of YTHDF1 Curtails FDX1 Translation to Drive Concurrent Multikinase Inhibitor Resistance and Cuproptosis Tolerance. Cancer Communications. https://doi.org/10.34133/cancomm.0048

Vancouver

Wang W, Jiang X, Chen X, Liang K, Chen M, Lu K, et al. NBR1-Mediated Autophagic Degradation of YTHDF1 Curtails FDX1 Translation to Drive Concurrent Multikinase Inhibitor Resistance and Cuproptosis Tolerance. Cancer Communications. 2026. doi:10.34133/cancomm.0048

BibTeX
@article{Wang2026,
  author = {Wang, Weikai and Jiang, Xin and Chen, Xiaona and Liang, Kaiyu and Chen, Miaoqin and Lu, Kaizhong and Wei, Qi and Wu, Yuchen and Zhu, Liyuan and Chen, Yuan and Hou, Tianlun and Luo, Jingfeng and Li, Chentao and Wang, Xian and Jin, Hongchuan and Feng, Lifeng},
  title = {NBR1-Mediated Autophagic Degradation of YTHDF1 Curtails FDX1 Translation to Drive Concurrent Multikinase Inhibitor Resistance and Cuproptosis Tolerance},
  journal = {Cancer Communications},
  year = {2026},
  doi = {10.34133/cancomm.0048}
}
Kostenlos starten →